Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05595447 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2/3
Started2022-10-18
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 12, 2025 (before its estimated October 18, 2025 completion). Its status may not reflect the trial's current state.
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?

Amendment record

Amended 2 times since 2022-10-24; most recent filed 2025-03-10. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-03-10
Amendment Study Status v2
2024-02-22
Amendment Study Status v1
2022-10-24
Original filing
Trial Details
NCT Number NCT05595447
Lead Sponsor Hospital Regional de Alta Especialidad del Bajio
Collaborators: Universidad de Guanajuato
Conditions Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
Enrollment 20 participants
Start Date 2022-10-18
Primary Completion 2025-10-18 (estimated)
Study Completion 2025-10-18 (estimated)
Updated on ClinicalTrials.gov 2025-03-12